GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (NEOE:MYCO) » Definitions » Change In Receivables

Mydecine Innovations Group (NEOE:MYCO) Change In Receivables : C$0.11 Mil (TTM As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Mydecine Innovations Group Change In Receivables?

Mydecine Innovations Group's change in receivables for the quarter that ended in Sep. 2023 was C$0.02 Mil. It means Mydecine Innovations Group's Accounts Receivable declined by C$0.02 Mil from Jun. 2023 to Sep. 2023 .

Mydecine Innovations Group's change in receivables for the fiscal year that ended in Dec. 2022 was C$-0.18 Mil. It means Mydecine Innovations Group's Accounts Receivable increased by C$0.18 Mil from Dec. 2021 to Dec. 2022 .

Mydecine Innovations Group's Accounts Receivable for the quarter that ended in Sep. 2023 was C$0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Mydecine Innovations Group's liquidation value for the three months ended in Sep. 2023 was C$-10.96 Mil.


Mydecine Innovations Group Change In Receivables Historical Data

The historical data trend for Mydecine Innovations Group's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group Change In Receivables Chart

Mydecine Innovations Group Annual Data
Trend Dec13 Aug14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.01 -0.19 -0.18

Mydecine Innovations Group Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 -0.15 0.01 0.23 0.02

Mydecine Innovations Group Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mydecine Innovations Group  (NEOE:MYCO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Mydecine Innovations Group's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

2. In Ben Graham's calculation of liquidation value, Mydecine Innovations Group's accounts receivable are only considered to be worth 75% of book value:

Mydecine Innovations Group's liquidation value for the quarter that ended in Sep. 2023 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.017-10.972+0.75 * 0+0.5 * 0
=-10.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mydecine Innovations Group Change In Receivables Related Terms

Thank you for viewing the detailed overview of Mydecine Innovations Group's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Mydecine Innovations Group (NEOE:MYCO) Business Description

Traded in Other Exchanges
Address
789 West Pender Street, Suite 810, Vancouver, BC, CAN, V6C 1H2
Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.

Mydecine Innovations Group (NEOE:MYCO) Headlines

No Headlines